Title: Characteristics, clinical outcomes and patient-reported outcomes of patients with
ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European
countries
Version: 1 Date: 10 Nov 2022
Reviewer's report:
There are still few reports on tofacitinib for UC, and this large-scale data is a very interesting
paper. I have a few questions.
# Table 2 shows patient backgrounds by history of biologics treatment, but it would be easier to
understand the content of the article if there was a background table for all patients.
# As for the method, I think it would be better if you specifically described the primary and
secondary endpoints.
# Did you analyze in table2 for each?
# You mentioned extra-intestinal complications on page 9. What kind of extra-intestinal
complications?
# In the item of disease activity during tofacitinib treatment on page 10, it is said that many of
the target patients are moderate to severe patients. What is the proportion of each?
Title: Characteristics, clinical outcomes and patient-reported outcomes of patients with
ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European
countries
Version: 1 Date: 10 Nov 2022
Reviewer's report:
There are still few reports on tofacitinib for UC, and this large-scale data is a very interesting
paper. I have a few questions.
# Table 2 shows patient backgrounds by history of biologics treatment, but it would be easier to
understand the content of the article if there was a background table for all patients.
# As for the method, I think it would be better if you specifically described the primary and
secondary endpoints.
# Did you analyze in table2 for each?
# You mentioned extra-intestinal complications on page 9. What kind of extra-intestinal
complications?
# In the item of disease activity during tofacitinib treatment on page 10, it is said that many of
the target patients are moderate to severe patients. What is the proportion of each?
Please review this paper.
user
Title: Characteristics, clinical outcomes and patient-reported outcomes of patients with
ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European
countries
Version: 1 Date: 10 Nov 2022
Reviewer's report:
There are still few reports on tofacitinib for UC, and this large-scale data is a very interesting
paper. I have a few questions.
# Table 2 shows patient backgrounds by history of biologics treatment, but it would be easier to
understand the content of the article if there was a background table for all patients.
# As for the method, I think it would be better if you specifically described the primary and
secondary endpoints.
# Did you analyze in table2 for each?
# You mentioned extra-intestinal complications on page 9. What kind of extra-intestinal
complications?
# In the item of disease activity during tofacitinib treatment on page 10, it is said that many of
the target patients are moderate to severe patients. What is the proportion of each?
assistant